Skip to main content

Shingles

10
Pipeline Programs
8
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
2
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
7100%
+ 6 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
3 programs
1
1
1
Zoster Vaccine LivePhase 4Vaccine1 trial
Zoster Vaccine, LivePhase 3Vaccine1 trial
zoster vaccine livePhase 2Vaccine1 trial
Active Trials
NCT00109122Completed180Est. Jul 2006
NCT00534248Completed22,439Est. Jan 2010
NCT02624375Completed10Est. Nov 2019
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
1
1
1
Zoster Vaccine LivePhase 4Vaccine
Zoster Vaccine, LivePhase 3Vaccine
zoster vaccine livePhase 2Vaccine
Pfizer
PfizerNEW YORK, NY
1 program
1
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for InjectionPhase 1/2
BioNTech
BioNTechCA - San Diego
1 program
1
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for InjectionPhase 1/21 trial
Active Trials
NCT05703607Terminated484Est. Sep 2025
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
ZostavaxPhase 1
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
ZostavaxPhase 11 trial
Active Trials
NCT02114333Completed160Est. May 2020
Dynavax Technologies
Dynavax TechnologiesCA - Emeryville
2 programs
Z-1018PHASE_11 trial
Z-1018PHASE_1_21 trial
Active Trials
NCT05245838Completed150Est. Oct 2022
NCT06569823Recruiting764Est. Nov 2031
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Zoster Vaccine LivePHASE_4Vaccine

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
MSDZoster Vaccine Live
MSDZoster Vaccine, Live
MSDzoster vaccine live
Dynavax TechnologiesZ-1018
BioNTechCandidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
Dynavax TechnologiesZ-1018
Colorado TherapeuticsZostavax

Clinical Trials (7)

Total enrollment: 24,187 patients across 7 trials

NCT02624375MSDZoster Vaccine Live

Immune Response to Shingles Vaccination

Start: Feb 2016Est. completion: Nov 201910 patients
Phase 4Completed
NCT00534248MSDZoster Vaccine, Live

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

Start: Oct 2007Est. completion: Jan 201022,439 patients
Phase 3Completed
NCT00109122MSDzoster vaccine live

Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)

Start: Nov 2001Est. completion: Jul 2006180 patients
Phase 2Completed
NCT06569823Dynavax TechnologiesZ-1018

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

Start: Jun 2024Est. completion: Nov 2031764 patients
Phase 1/2Recruiting
NCT05703607BioNTechCandidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Start: Jan 2023Est. completion: Sep 2025484 patients
Phase 1/2Terminated
NCT05245838Dynavax TechnologiesZ-1018

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Start: Jan 2022Est. completion: Oct 2022150 patients
Phase 1Completed
NCT02114333Colorado TherapeuticsZostavax

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Start: May 2014Est. completion: May 2020160 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 24,187 patients
Vaccine is the dominant modality (100% of programs)
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.